{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:54:48Z","timestamp":1767848088105,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T00:00:00Z","timestamp":1716681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T00:00:00Z","timestamp":1716681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s10549-024-07367-x","type":"journal-article","created":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T19:01:26Z","timestamp":1716750086000},"page":"253-261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study"],"prefix":"10.1007","volume":"207","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5545-5817","authenticated-orcid":false,"given":"Ayaka","family":"Isogai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0277-8196","authenticated-orcid":false,"given":"Kazuki","family":"Nozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4427-6888","authenticated-orcid":false,"given":"Akira","family":"Nakakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Komaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8382-7473","authenticated-orcid":false,"given":"Yuri","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8415-3885","authenticated-orcid":false,"given":"Yuka","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4317-3804","authenticated-orcid":false,"given":"Ayumi","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0355-9294","authenticated-orcid":false,"given":"Haruru","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5274-9158","authenticated-orcid":false,"given":"Akiyo","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0935-9269","authenticated-orcid":false,"given":"Masaya","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2927-9258","authenticated-orcid":false,"given":"Masataka","family":"Sawaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0242-4718","authenticated-orcid":false,"given":"Hiroji","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,26]]},"reference":[{"key":"7367_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235:177\u2013182. https:\/\/doi.org\/10.1126\/science.3798106","journal-title":"Science"},{"key":"7367_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science 244:707\u2013712. https:\/\/doi.org\/10.1126\/science.2470152","journal-title":"Science"},{"key":"7367_CR3","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783\u2013792. https:\/\/doi.org\/10.1056\/NEJM200103153441101","journal-title":"N Engl J Med"},{"key":"7367_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cort\u00e9s J, Kim S-B et al (2012) Pertuzumab plus Trastuzumab plus Docetaxel for metastatic breast cancer. N Engl J Med 366:109\u2013119. https:\/\/doi.org\/10.1056\/NEJMoa1113216","journal-title":"N Engl J Med"},{"key":"7367_CR5","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L et al (2012) Trastuzumab Emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783\u20131791. https:\/\/doi.org\/10.1056\/NEJMoa1209124","journal-title":"N Engl J Med"},{"key":"7367_CR6","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/nejmoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T et al (2020) Trastuzumab Deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 382:610\u2013621. https:\/\/doi.org\/10.1056\/nejmoa1914510","journal-title":"N Engl J Med"},{"key":"7367_CR7","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/nejmoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim S-B, Chung W-P et al (2022) Trastuzumab Deruxtecan versus Trastuzumab Emtansine for breast cancer. N Engl J Med 386:1143\u20131154. https:\/\/doi.org\/10.1056\/nejmoa2115022","journal-title":"N Engl J Med"},{"key":"7367_CR8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jamaoncol.2020.7932","volume":"7","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Im S-A, Cardoso F et al (2021) Efficacy of Margetuximab vs Trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer. JAMA Oncol 7:573. https:\/\/doi.org\/10.1001\/jamaoncol.2020.7932","journal-title":"JAMA Oncol"},{"key":"7367_CR9","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus Capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733\u20132743. https:\/\/doi.org\/10.1056\/NEJMoa064320","journal-title":"N Engl J Med"},{"key":"7367_CR10","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1200\/JCO.20.00147","volume":"38","author":"C Saura","year":"2020","unstructured":"Saura C, Oliveira M, Feng Y-H et al (2020) Neratinib plus Capecitabine versus Lapatinib plus Capecitabine in HER2-positive metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: phase III NALA Trial. J Clin Oncol 38:3138\u20133149. https:\/\/doi.org\/10.1200\/JCO.20.00147","journal-title":"J Clin Oncol"},{"key":"7367_CR11","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy RK, Loi S, Okines A et al (2020) Tucatinib, Trastuzumab, and Capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 382:597\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa1914609","journal-title":"N Engl J Med"},{"key":"7367_CR12","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","volume":"401","author":"F Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 F, Hee Park Y, Kim S-B et al (2023) Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 401:1773\u20131785. https:\/\/doi.org\/10.1016\/S0140-6736(23)00725-0","journal-title":"Lancet"},{"key":"7367_CR13","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1186\/s12885-021-08504-1","volume":"21","author":"T Nakayama","year":"2021","unstructured":"Nakayama T, Yoshinami T, Yasojima H et al (2021) Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and\/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917). BMC Cancer 21:795. https:\/\/doi.org\/10.1186\/s12885-021-08504-1","journal-title":"BMC Cancer"},{"key":"7367_CR14","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s12282-020-01192-y","volume":"28","author":"T Yokoe","year":"2021","unstructured":"Yokoe T, Kurozumi S, Nozawa K et al (2021) Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B). Breast Cancer 28:581\u2013591. https:\/\/doi.org\/10.1007\/s12282-020-01192-y","journal-title":"Breast Cancer"},{"key":"7367_CR15","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","volume":"28","author":"KL Blackwell","year":"2010","unstructured":"Blackwell KL, Burstein HJ, Storniolo AM et al (2010) Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124\u20131130. https:\/\/doi.org\/10.1200\/JCO.2008.21.4437","journal-title":"J Clin Oncol"},{"key":"7367_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s13643-022-02134-9","volume":"11","author":"Y Yuan","year":"2022","unstructured":"Yuan Y, Liu X, Cai Y, Li W (2022) Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis. Syst Rev 11:264. https:\/\/doi.org\/10.1186\/s13643-022-02134-9","journal-title":"Syst Rev"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07367-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-024-07367-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07367-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T12:56:26Z","timestamp":1722603386000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-024-07367-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,26]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["7367"],"URL":"https:\/\/doi.org\/10.1007\/s10549-024-07367-x","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,26]]},"assertion":[{"value":"15 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"The study protocol was approved by the Certified Review Board of Aichi Cancer Center Hospital (Nagoya, Aichi, Japan), and the study was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all patients in the form of opt-out on the website.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}